New Quality of Life Tool Developed for Rare Adrenal Cancer Patients
Italian researchers create first validated questionnaire to measure quality of life in adrenocortical carcinoma patients.
Summary
Researchers developed and validated the first specialized quality of life questionnaire for patients with adrenocortical carcinoma (ACC), a rare and aggressive adrenal gland cancer. The QoLACC tool measures physical symptoms, emotional wellbeing, financial burden, and spiritual concerns specific to ACC patients. Testing with 37 patients showed the questionnaire has excellent reliability and validity. This addresses a critical gap since existing quality of life measures don't capture the unique challenges ACC patients face, including hormone-related symptoms and treatment side effects. The tool will help healthcare providers better understand and support these patients' comprehensive needs beyond just medical treatment.
Detailed Summary
Adrenocortical carcinoma (ACC) is a rare but aggressive cancer affecting the adrenal glands that significantly impacts patients' quality of life through cancer symptoms, treatment effects, and psychological burden. Until now, no validated tool existed to comprehensively measure quality of life specifically for ACC patients.
Italian researchers at the University of Brescia developed the QoLACC questionnaire, the first instrument designed specifically for ACC patients. The development process involved 15 patients and 15 physicians evaluating item comprehensibility and clinical relevance, followed by validation testing with 37 consecutive ACC patients.
The questionnaire demonstrated excellent psychometric properties, with content validity scores of 0.93-1.00 and reliability coefficient of 0.870. Strong correlations were found between QoLACC sections and established quality of life measures, confirming the tool's validity. The questionnaire covers physical symptoms, emotional wellbeing, financial concerns, and spiritual aspects unique to ACC patients.
This development represents a significant advancement in cancer care, as quality of life assessment is crucial for comprehensive patient management and treatment decisions. The tool enables healthcare providers to systematically identify and address patient concerns beyond medical symptoms, potentially improving overall outcomes and patient satisfaction. While this study focused on Italian patients, the questionnaire could be adapted for international use, filling a critical gap in rare cancer care assessment tools.
Key Findings
- First validated quality of life questionnaire developed specifically for adrenocortical carcinoma patients
- QoLACC tool showed excellent reliability with 0.870 correlation coefficient in 37-patient validation study
- Questionnaire covers physical, emotional, financial, and spiritual aspects unique to ACC patients
- Strong correlations found between QoLACC and established quality of life measures, confirming validity
Methodology
Study conducted October 2024-January 2025 with 15 patients and physicians evaluating item relevance, followed by psychometric validation in 37 consecutive ACC patients. Test-retest reliability and construct validity assessed using co-administered validated scales.
Study Limitations
Small sample size of 37 patients limits generalizability. Study conducted only in Italian population at single center. Long-term validation and international adaptation needed before widespread clinical implementation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.